Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
06/24/2008
Trade Name:
Viramune Tablets 200 mg Viramune Oral Suspension 10 mg/mL
Generic or Proper Name (*):
nevirapine
Indications Studied:
Use in combination with other antiretroviral agents for the treatment of HIV-1 infection
Therapeutic Category:
Antiviral
Ages Studied:
15 days - <16 years
Study #:
1
Study Type:
Safety/Pharmacokinetic/Tolerability
Study Design:
Open Label/Traditional Pharmacokinetic
No Patients:
123
No Centers:
4
No Countries:
1
BPCA(B), PREA(P):
P
-
-